State of Precision Oncology: An Australian Perspective

ABSTRACT Precision oncology is redefining cancer therapeutics worldwide. In Australia, the integration of genomic medicine into routine clinical oncology remains inconsistently constrained by fragmented funding mechanisms, regional disparities, and a limited workforce. Understanding these structural and policy challenges is crucial for transitioning toward a sustainable, equitable genomic health ecosystem. This narrative review synthesizes evidence from national policy frameworks, peer-reviewed literature, and translational oncology initiatives to examine the current state of precision oncology in Australia. Key domains of analysis include clinical practice patterns, access and equity, infrastructure, data governance, regulatory oversight, and health-policy reform. Although major initiatives, such as Omico’s Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) platform, the ZERO Childhood Cancer Program, and the forthcoming national coordination body Genomics Australia, demonstrate substantial progress, significant implementation barriers persist. Australia stands on the cusp of realizing a genomics-enabled model of cancer care. Consolidation of national governance under Genomics Australia, expansion of Medicare Benefits Schedule reimbursement for comprehensive genomic profiling, and integration of digital-innovation platforms will be pivotal to achieving an internationally replicable model for responsible, population-wide precision oncology.